Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs. Proceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity.

Mark Cohen, a Senior Partner and the Chair of the Life Science Practice Group at Pearl Cohen, represents Biosight in intellectual property matters.

Click here for for article.